文献速递牙周病

Kava-241减轻胶原抗体致敏的牙龈卟啉单胞菌牙周炎模型中的牙周破坏

Kava-241 reduced periodontal destruction in a collagen antibody primed Porphyromonas gingivalis model of periodontitis.
PubMed 文献 · J Clin Periodontol · 2017-09-21

该研究在小鼠胶原抗体致敏的牙龈卟啉单胞菌口腔灌胃牙周炎模型中评估Kava-241的效果。结果显示Kava-241显著减少上皮向下增殖(72%)和牙槽骨丧失(36%),并降低软组织炎症细胞计数、增加成纤维细胞,提示其有望用于牙周炎炎症和骨丧失的防治。

要点

  • Kava-241显著减少上皮向下增殖72%和牙槽骨丧失36%。
  • Kava-241降低软组织炎症细胞计数并增加成纤维细胞。
  • 胶原抗体致敏联合口腔灌胃是可快速重复的牙周破坏模型。

核心结论

  • Kava-241在胶原抗体致敏的牙龈卟啉单胞菌牙周炎模型中减轻牙周破坏,在炎症和牙槽骨丧失防治方面显示前景。
  • 仍需进一步实验确定该治疗药物作用的分子通路。

研究设计与样本

  • 小鼠实验性牙周炎通过15天口腔灌胃牙龈卟啉单胞菌+II型胶原抗体诱导。
  • 小鼠在灌胃同时或之前接受Kava-241治疗,并与未治疗小鼠比较,进行组织形态计量学分析。

主要发现

  • 口腔灌胃牙龈卟啉单胞菌诱导轻度上皮向下增殖和牙槽骨丧失。
  • 额外抗体致敏组较单纯灌胃组组织破坏更严重(p < .05)。
  • Kava-241治疗显著减少牙龈卟啉单胞菌+抗体组上皮向下增殖(72%)和牙槽骨丧失(36%)(p < .05)。
  • Kava-241效果与软组织内炎症细胞计数减少和成纤维细胞增加相关(p < .05)。

临床怎么用

  • Kava-241可能作为牙周炎炎症和牙槽骨丧失的潜在防治药物,但尚需进一步实验确定分子通路。

局限性

  • 需进一步实验确定Kava-241作用的分子通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of this study was to evaluate the effect of Kava-241, an optimized Piper methysticum Kava compound, on periodontal destruction in a collagen antibody primed oral gavage model of periodontitis. METHODS: Experimental periodontitis was induced by oral gavage of Porphyromonas gingivalis (P. gingivalis) + type II collagen antibody (AB) in mice during 15 days. Mice were treated with Kava-241 concomitantly or prior to P. gingivalis gavage and compared to untreated mice. Comprehensive histomorphometric analyses were performed. RESULTS: Oral gavage with P. gingivalis induced mild epithelial down-growth and alveolar bone loss, while oral gavage with additional AB priming had greater tissular destruction in comparison with gavage alone (p < .05). Kava-241 treatment significantly (p < .05) reduced epithelial down-growth (72%) and alveolar bone loss (36%) in P. gingivalis+AB group. This Kava-241 effect was associated to a reduction in inflammatory cell counts within soft tissues and an increase in fibroblasts (p < .05). CONCLUSION: Priming with type II collagen antibody with oral gavage is a fast and reproducible model of periodontal destruction adequate for the evaluation of novel therapeutics. The effect of Kava-241 shows promise in the prevention and treatment of inflammation and alveolar bone loss associated with periodontitis. Further experiments are required to determine molecular pathways targeted by this therapeutic agent.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Alshammari A, Patel J, Al-Hashemi J, et al. Kava-241 reduced periodontal destruction in a collagen antibody primed Porphyromonas gingivalis model of periodontitis. J Clin Periodontol. 2017. PMID: 28746780. doi:10.1111/jcpe.12784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。